Targeting specific KRAS mutations in cancer treatment
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
This study is exploring new treatments for people with aggressive cancers like lung, colon, and pancreatic cancer that have a specific mutation called KRAS G12V, using a special technique to target and turn off the bad gene while keeping healthy cells safe.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enfuego Therapeutics INC. NIH-funded |
| Lab location | 1 site (Pittsboro, United States) |
| Project ID | NIH-11116069 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies that specifically target the KRAS G12V mutation, which is prevalent in several aggressive cancers such as lung, colon, and pancreatic cancers. By utilizing RNA interference (RNAi) technology, the approach aims to selectively silence the mutant KRAS gene while preserving the normal gene function in healthy tissues. This targeted method could potentially overcome the challenges faced in treating cancers driven by KRAS mutations, which have been historically difficult to address with conventional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, colon cancer, or pancreatic cancer that harbor the KRAS G12V mutation.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with KRAS G12V mutant cancers.
How similar studies have performed: While there have been some advancements in targeting KRAS mutations, this specific approach using RNAi for the G12V mutation is relatively novel and has not been extensively tested.
Where this research is happening
Pittsboro, United States
- Enfuego Therapeutics INC. — Pittsboro, United States (Active)
Researchers
- Principal investigator: Stanland, Lyla — Enfuego Therapeutics INC.
- Study coordinator: Stanland, Lyla
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.